Login to Your Account

Partnership, phase III next for Chemocentryx after phase II DN data

By Jennifer Boggs
Managing Editor

Friday, December 12, 2014

Ending the year in a much better position than it started, Chemocentryx Inc. reported positive data from its 52-week phase II study of CCR2 inhibitor CCX140 in diabetic nephropathy (DN), positioning the drug for phase III development and, hopefully, a partnership.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription